AbbVie's Earnings: A Guidance Reset That Missed the Whisper Number

The market's reaction was a classic case of "sell the news." On February 4, AbbVie posted a clear beat, but the stock fell anyway. The core expectation gap was simple: the strong immunology growth that powered the quarter was already fully priced in. Investors had been waiting for confirmation that Skyrizi and Rinvoq could fill the Humira void, and the company delivered. The problem was, the beat was the expected outcome.

The numbers showed a clean win. AbbVie earned an adjusted quarterly profit of $2.71 per share, topping the average analyst forecast of $2.65. The key driver was the performance of its newer immunology drugs. Skyrizi recorded sales of $5.01 billion, a 32.5% jump that beat estimates. While Rinvoq sales also grew, the real story was the combined strength that fueled the beat. This was the whisper number, and the print met it.

Yet the stock dropped. The reason lies in the guidance reset that followed. While the company raised its full-year outlook, the market was looking past the headline beat to the details. The guidance, while above consensus, may have been seen as a modest reset rather than a surprise acceleration. In this setup, the strong quarter was the rumor that had already been bought. The stock's decline was the natural sell-off once the reality matched the high expectations.

The Guidance Reset: A Sandbagged Raise?

The stock's decline wasn't just about the quarter; it was a reaction to the forward view. While AbbVie raised its full-year 2026 outlook, the guidance reset may have signaled a more cautious management view than the market hoped for. The company now expects adjusted annual profit per share of between $14.37 and $14.57, a range that sits above the analyst consensus of $14.24. On the surface, it's an increase. But the real story is in the implied trajectory.

This raise comes after a standout year of 8.6 percent operational revenue growth in 2025. The new guidance implies a slowdown. To hit the midpoint of the $14.37-$14.57 range from a base that includes the strong fourth-quarter beat, the company must grow earnings at a notably lower pace than it did last year. In other words, the guidance reset the market's expectations for the top-line expansion that was needed to fully offset the Humira decline.

<p>

This fundamental tension is reflected in the stock's price action. Despite the recent earnings beat, AbbVie shares have underperformed both the broader market and its medical sector peers. This relative weakness is the market's verdict on sustainability. When a stock trades below its benchmark over time, it signals that investors are pricing in a lower growth trajectory or higher risk than the consensus. In AbbVie's case, the guidance reset and the segment-specific headwinds appear to have reinforced that discount. The market is looking past the immunology strength and focusing on the broader picture: a company navigating a difficult transition where new growth is being challenged by legacy declines and new competitive pressures.

Catalysts and Risks: The Next Expectation Shift

The current valuation gap hinges on a few near-term events that will test whether the market's cautious view is justified or if a reset is overdue. The first and most immediate catalyst is the next earnings report. That quarter will serve as a reality check against the raised 2026 guidance. The market will be watching for signs that the company can accelerate past the implied slowdown, especially given the low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026. Any stumble in hitting the midpoint of the $14.37-$14.57 per-share range could widen the gap, confirming concerns about growth sustainability.

Beyond the quarterly beat, the pipeline offers the next major potential catalyst. Positive data readouts for Rinvoq in 2026 could be a game-changer. The drug is expected to gain approvals for two new indications in 2026, and phase III data for hidradenitis suppurativa and lupus are also due. Each approval adds a new revenue stream and could help offset pricing pressures. The market has already priced in a strong immunology story, but a faster-than-expected pipeline ramp would reset expectations higher, potentially closing the valuation gap.

On the other side of the ledger, risks are tied to execution and sentiment. The stock's reaction to its recent dividend declaration will be telling. While the board's move to pay a $1.73 per share quarterly dividend reinforces its income profile, it may also signal a focus on returning capital rather than aggressive reinvestment, which could dampen growth narratives. More broadly, the stock's underperformance relative to peers suggests institutional investors are weighing the mixed fundamental picture. The combination of weakness in the aesthetics segment and a decline in oncology sales creates a headwind that a simple immunology beat cannot fully overcome. Until these pressures ease, the market's discount is likely to persist.

The bottom line is that the next expectation shift will be driven by the interplay of these catalysts and risks. The stock's path will depend on whether the company can deliver a beat-and-raise narrative that exceeds the modest guidance reset, or if the headwinds prove more durable than the market currently assumes. For now, the setup favors patience over panic.